Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.

Tytuł :
Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Autorzy :
Xiaoyan C; a The First Affiliated Hospital of Guangzhou Medical University , Endocrinology Department , Guangzhou , China.
Jing W; a The First Affiliated Hospital of Guangzhou Medical University , Endocrinology Department , Guangzhou , China.
Xiaochun H; a The First Affiliated Hospital of Guangzhou Medical University , Endocrinology Department , Guangzhou , China.
Yuyu T; a The First Affiliated Hospital of Guangzhou Medical University , Endocrinology Department , Guangzhou , China.
Shunyou D; a The First Affiliated Hospital of Guangzhou Medical University , Endocrinology Department , Guangzhou , China.
Yingyu F; a The First Affiliated Hospital of Guangzhou Medical University , Endocrinology Department , Guangzhou , China.
Pokaż więcej
Źródło :
Current medical research and opinion [Curr Med Res Opin] 2016 Jun; Vol. 32 (6), pp. 1131-6. Date of Electronic Publication: 2016 Mar 23.
Typ publikacji :
Journal Article; Randomized Controlled Trial
Język :
English
Imprint Name(s) :
Publication: 1995- : Newbury, Berkshire, U.K. : Informa Healthcare
Original Publication: London, M. D. Promotions, ltd.
MeSH Terms :
Adamantane/*analogs & derivatives
Diabetes Mellitus, Type 2/*blood
Diabetes Mellitus, Type 2/*drug therapy
Dipeptides/*therapeutic use
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Hypoglycemic Agents/*therapeutic use
Nitriles/*therapeutic use
Pyrrolidines/*therapeutic use
Adamantane/therapeutic use ; Aged ; Asian Continental Ancestry Group ; Blood Glucose/metabolism ; China ; Drug Therapy, Combination ; Female ; Gliclazide/therapeutic use ; Glycated Hemoglobin A/metabolism ; Humans ; Male ; Metformin/therapeutic use ; Middle Aged ; Prospective Studies ; Sulfonylurea Compounds/therapeutic use ; Vildagliptin
Contributed Indexing :
Keywords: Acute glucose fluctuation*; CGMS*; Chinese type 2 diabetes mellitus*; DPP-4 inhibitors*
Molecular Sequence :
ChiCTR ChiCTR-TRC-13003858
Substance Nomenclature :
0 (Blood Glucose)
0 (Dipeptides)
0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Glycated Hemoglobin A)
0 (Hypoglycemic Agents)
0 (Nitriles)
0 (Pyrrolidines)
0 (Sulfonylurea Compounds)
9100L32L2N (Metformin)
9GB927LAJW (saxagliptin)
G4PX8C4HKV (Gliclazide)
I6B4B2U96P (Vildagliptin)
PJY633525U (Adamantane)
Entry Date(s) :
Date Created: 20160308 Date Completed: 20170912 Latest Revision: 20181202
Update Code :
20210210
DOI :
10.1185/03007995.2016.1162773
PMID :
26950829
Czasopismo naukowe
Objective The present study aimed to compare the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin and saxagliptin on 24 hour acute glucose fluctuations in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with a combination of metformin and sulfonylurea. Research design and methods This was a 24 week, prospective, randomized, open-label, active-controlled study. Patients (N = 73) with T2DM who had inadequate glycemic control (HbA1c 7.0%-10.0%) with a stable dosage of metformin plus gliclazide for more than 3 months were randomized to receive either vildagliptin 50 mg twice daily (BID, n = 37) or saxagliptin 5 mg once daily (QD, n = 36). Change in mean amplitude of glycemic excursions (MAGE) was assessed at the end of 24 weeks. Results At baseline, the mean (±SD) age was 62.9 ± 6.55 years, disease duration was 7.0 ± 2.33 years, and HbA1c was 8.4 ± 0.68%. After 24 weeks of treatment, the MAGE decreased from 5.81 ± 1.16 mmol/L to 4.06 ± 0.86 mmol/L (p<0.001) in the vildagliptin group and from 5.66 ± 1.14 mmol/L to 4.79 ± 1.25 mmol/L (p = 0.003) in the saxagliptin group. The mean change in MAGE in the vildagliptin group was significantly greater than that in the saxagliptin group (1.74 ± 0.48 mmol/L vs. 0.87 ± 0.40 mmol/L, p<0.001). The mean change in HbA1c, from baseline to the study endpoint, in the vildagliptin and saxagliptin groups, was 1.22 ± 0.40% and 1.07 ± 0.36%, respectively, with no significant difference between the groups (p = 0.091). The overall safety and tolerability of vildagliptin and saxagliptin were similar. The limitations of the study were a small number of patients and open-label administration of the study drug. Conclusion Vildagliptin produced a significantly greater reduction in acute glucose fluctuations compared with saxagliptin when added to a dual combination of metformin and sulfonylurea in Chinese patients with T2DM. Chinese clinical trial registration number ChiCTR-TRC-13003858.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies